Vanguard Capital Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Vanguard Capital Management's CTKB Position: Q3 2026 in Review
Vanguard Capital Management reduced its Cytek Biosciences (CTKB) stake by 1.1% in Q3 2026, selling an estimated $249K and leaving 4,887,083 shares worth $29.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.
Vanguard Capital Management first reported a position in CTKB in Q1 2026 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Vanguard Capital Management held 4,887,083 shares of Cytek Biosciences worth $29.1M as of Q3 2026.
- Vanguard Capital Management sold 52,514 Cytek Biosciences shares in Q3 2026, an estimated $249K.
- Cytek Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2196 holding.
- Vanguard Capital Management first reported a position in Cytek Biosciences in Q1 2026 and has held it in 3 quarters since.
- 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.